122 related articles for article (PubMed ID: 29105782)
1. Toxicity effects of AgZnO nanoparticles and rifampicin on Mycobacterium tuberculosis into the macrophage.
Jafari A; Jafari Nodooshan S; Safarkar R; Movahedzadeh F; Mosavari N; Novin Kashani A; Dehghanpour M; Kamalzadeh M; Rasouli Koohi S; Fathizadeh S; Majidpour A
J Basic Microbiol; 2018 Jan; 58(1):41-51. PubMed ID: 29105782
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal impact of Ag, ZnO and mixed AgZnO colloidal nanoparticles on H
Jafari A; Mosavari N; Movahedzadeh F; Nodooshan SJ; Safarkar R; Moro R; Kamalzadeh M; Majidpour A; Boustanshenas M; Mosavi T
Microb Pathog; 2017 Sep; 110():335-344. PubMed ID: 28710015
[TBL] [Abstract][Full Text] [Related]
3. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.
Vibe CB; Fenaroli F; Pires D; Wilson SR; Bogoeva V; Kalluru R; Speth M; Anes E; Griffiths G; Hildahl J
Nanotoxicology; 2016 Aug; 10(6):680-8. PubMed ID: 26573343
[TBL] [Abstract][Full Text] [Related]
4. Multimetallic Microparticles Increase the Potency of Rifampicin against Intracellular Mycobacterium tuberculosis.
Ellis T; Chiappi M; García-Trenco A; Al-Ejji M; Sarkar S; Georgiou TK; Shaffer MSP; Tetley TD; Schwander S; Ryan MP; Porter AE
ACS Nano; 2018 Jun; 12(6):5228-5240. PubMed ID: 29767993
[TBL] [Abstract][Full Text] [Related]
5. Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular M.tuberculosis killing efficiency.
Pi J; Shen L; Shen H; Yang E; Wang W; Wang R; Huang D; Lee BS; Hu C; Chen C; Jin H; Cai J; Zeng G; Chen ZW
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109777. PubMed ID: 31349400
[TBL] [Abstract][Full Text] [Related]
6. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
7. Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages.
Tukulula M; Gouveia L; Paixao P; Hayeshi R; Naicker B; Dube A
Pharm Res; 2018 Mar; 35(6):111. PubMed ID: 29600438
[TBL] [Abstract][Full Text] [Related]
8. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
Carneiro SP; Carvalho KV; de Oliveira Aguiar Soares RD; Carneiro CM; de Andrade MHG; Duarte RS; Dos Santos ODH
Colloids Surf B Biointerfaces; 2019 Mar; 175():306-313. PubMed ID: 30553206
[TBL] [Abstract][Full Text] [Related]
9. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles.
Clemens DL; Lee BY; Xue M; Thomas CR; Meng H; Ferris D; Nel AE; Zink JI; Horwitz MA
Antimicrob Agents Chemother; 2012 May; 56(5):2535-45. PubMed ID: 22354311
[TBL] [Abstract][Full Text] [Related]
10. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model.
Sarkar S; Sarkar D
J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731
[TBL] [Abstract][Full Text] [Related]
11. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages.
Chanwong S; Maneekarn N; Makonkawkeyoon L; Makonkawkeyoon S
Tuberculosis (Edinb); 2007 Mar; 87(2):130-3. PubMed ID: 16860611
[TBL] [Abstract][Full Text] [Related]
12. Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
Canezin PH; Caleffi-Ferracioli KR; Scodro RBL; Siqueira VLD; Pavan FR; Barros ILE; Cardoso RF
J Antimicrob Chemother; 2018 Jul; 73(7):1770-1776. PubMed ID: 29579201
[TBL] [Abstract][Full Text] [Related]
13. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages.
Sood R; Rao M; Singhal S; Rattan A
Int J Antimicrob Agents; 2005 Jun; 25(6):464-8. PubMed ID: 15885988
[TBL] [Abstract][Full Text] [Related]
14. Gold Nanorods as Drug Delivery Vehicles for Rifampicin Greatly Improve the Efficacy of Combating Mycobacterium tuberculosis with Good Biocompatibility with the Host Cells.
Ali HR; Ali MR; Wu Y; Selim SA; Abdelaal HF; Nasr EA; El-Sayed MA
Bioconjug Chem; 2016 Oct; 27(10):2486-2492. PubMed ID: 27595304
[TBL] [Abstract][Full Text] [Related]
15. Zanthoxylum capense constituents with antimycobacterial activity against Mycobacterium tuberculosis in vitro and ex vivo within human macrophages.
Luo X; Pires D; Aínsa JA; Gracia B; Duarte N; Mulhovo S; Anes E; Ferreira MJ
J Ethnopharmacol; 2013 Mar; 146(1):417-22. PubMed ID: 23337743
[TBL] [Abstract][Full Text] [Related]
16. In vitro controlled release of Rifampicin through liquid-crystalline folate nanoparticles.
Parmar R; Misra R; Mohanty S
Colloids Surf B Biointerfaces; 2015 May; 129():198-205. PubMed ID: 25863713
[TBL] [Abstract][Full Text] [Related]
17. Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis.
Kumar P; Singh A; Sharma U; Singh D; Dobhal MP; Singh S
Pulm Pharmacol Ther; 2013 Jun; 26(3):332-5. PubMed ID: 23333815
[TBL] [Abstract][Full Text] [Related]
18. Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages.
Yunus Basha R; T S SK; Doble M
Carbohydr Polym; 2019 Aug; 218():53-62. PubMed ID: 31221343
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
20. An in vitro investigation of the bioactivities of ciprofloxacin and the new fluoroquinolone agents clinafloxacin (CI-960) and PD 131628 against Mycobacterium tuberculosis in human macrophages.
Van Rensburg CE; Jooné GK; Anderson R
Chemotherapy; 1995; 41(4):234-8. PubMed ID: 7555202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
